Technical Data
K0005-14N
Kallikrein 11, NT (KLK11, Hippostasin, hK11, Kallikrein-related Peptidase 11, MGC33060, Protease Serine 20 Trypsin-like, PRSS20, Serine Protease 20, Trypsin-like Serine Protease, TLSP, UNQ649/PRO1279)
Description:
Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. KLK11, also known as hippostatin, is a kallikrein-like serine protease, which has two alternatively spliced isoforms, brain-type and prostate-type. KLK11 plays a role in the prostate, including reproductive and/or tumorigenic functions. Elevated serum levels of KLLK11 arefound in 70% of women with ovarian cancer and in 60% of men with prostate cancer. Analysis of the KLK11 biomarker in serum may aid in the diagnosis and monitoring of ovarian and prostatic carcinoma.

Applications:
Suitable for use in ELISA and Western Blot. Other applications not tested.

Recommended Dilution:
ELISA: 1:1,000
Western Blot: 1:100-1:500
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
TypeIsotypeCloneGrade
PabIgGPurified
SizeStorageShippingSourceHost
100ug-20°CBlue IceHumanRabbit
Concentration:
~0.25mg/ml
Immunogen:
Synthetic peptide selected from the N-terminal region of human KLK11 (KLH).
Purity:
Purified by ammonium sulfate precipitation.
Form
Supplied as a liquid in PBS, 0.09% sodium azide.
Specificity:
Recognizes human KLK11.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1.Diamandis, E.P., et al., Clin. Biochem. 37(9):823-829 (2004). 2.Shigemasa, K., et al., Clin. Cancer Res. 10(8):2766-2770 (2004). 3.Borgono, C.A., et al., Int. J. Cancer 106(4):605-610 (2003). 4.Clark, H.F., et al., Genome Res. 13(10):2265-2270 (2003). 5.Nakamura, T., et al., Urology 61(5):1042-1046 (2003).